ClinicalTrials.gg
Active, not recruitingNCT06318273Updated Jun 17, 2026

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of ABBV-969 in Metastatic Castration-Resistant Prostate Cancer, sponsored by AbbVie. Active, not recruiting at 26 sites in 7 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-17.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 975 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
648th of 3,023
152 · median 48
Started
2024
with 174 others
Phase 1
615 of 3,596
83 open now
Primary completion
2027-05
later than 400 of 969 live
Registered
3,174th of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 648th largest by enrollment of the 3,023 interventional ones that give a count, is one of 175 that started in 2024, is one of 615 in phase 1, reaches primary completion later than 400 of the 969 other live ones, and was the 3,174th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,583 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,231 Prostatic Neoplasms studies recruiting now, 930 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy.

ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are parts to this study. Participants will receive ABBV-969 as a single agent at different doses. Approximately 230 adult participants will be enrolled in the study across sites worldwide.

In part 1 (dose escalation), ABBV-969 will be intravenously infused in escalating doses as a monotherapy. In part 2, multiple doses will be selected from Part 1 and mCRPC participants will be assigned to one of these doses in a randomized fashion to determine the recommended Phase 2 dose. The estimated duration of the study is up to 3 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • mCRPC
  • ABBV-969
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate.
  • Estimated > 6 months.
  • An (ECOG) performance status of 0 or 1.
  • Must have progressed on prior novel hormonal agents (NHAs) (e.g., abiraterone acetate and/or enzalutamide) for the treatment of prostate cancer and/or castration-resistant prostate cancer (CRPC). Determination of progression is done per local investigator according to (RECIST), version 1.1 and/or Prostate Cancer Working Group 3 (PCWG3).
  • Serum testosterone levels \<= 50 ng/dL (\<= 1.73 nmol/L) within the screening period and prior to the first dose of the study drug.
  • Must have received at least one NHA (e.g., enzalutamide and/or abiraterone). Additionally, participants must have received at least one taxane for prostate cancer (or are intolerant to, or unable to get access to taxanes).
  • Must have >= 1 metastatic lesion that is present on baseline computed tomography (CT), magnetic resonance imaging (MRI), or bone scan imaging obtained \<= 28 days prior to beginning study therapy.
  • Serum prostate specific antigen (PSA) level >= 1.0 ng/mL.
  • Availability of representative baseline tumor tissue (most recent archived tumor tissue after any novel hormonal agent (NHA) and/or any Prostate-Specific Membrane Antigen (PSMA) targeted therapy or fresh collected during screening if collecting a fresh biopsy at screening is deemed safe in the judgment of the investigator) suitable for immunohistochemistry (IHC) testing.
  • Laboratory values meeting the criteria laid out in the protocol.
  • corrected for heart rate (QTc) \<= 470 msec (using Fridericia's correction), no >= Grade 3 arrythmia, and no other cardiac abnormalities.

Exclusion criteria

Exclusion Criteria:

  • Unresolved Grade 2 or higher toxicities related to previous anticancer therapy except alopecia.
  • History of other active , as laid out in the protocol.
  • History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic , nor any evidence of active ILD or pneumonitis on screening chest CT scan.
  • History of or active idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
  • History of or active , intercurrent lung-specific illnesses including, but not limited to those listed in the protocol.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Part 1: ABBV-969 Monotherapy Dose Escalation

    Participants with metastatic castration-resistant prostate cancer (mCRPC) will receive ABBV-969 monotherapy once every 21 days

    Drug: ABBV-969

  • Experimental
    Part 2 A: Monotherapy Dose Expansion/Dose Optimization

    Participants with mCRPC will receive dose A of ABBV-969 (dose levels determined in Part 1) for dose optimization.

    Drug: ABBV-969

  • Experimental
    Part 2 B: Monotherapy Dose Expansion/Dose Optimization

    Participants with mCRPC will receive Dose B of ABBV-969 (dose levels determined in Part 1) for dose optimization.

    Drug: ABBV-969

Interventions

  • DrugABBV-969

    Intravenous (IV) Infusion

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to 3 Years

  2. Percentage of Participants Achieving Prostate Specific Antigen (PSA) response

    PSA response is defined as \>= 50% PSA decrease from baseline.

    Time frame: Up to 3 Years

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of ABBV-969

    Cmax is defined as the maximum observed plasma/serum concentration of ABBV-969.

    Time frame: Up to 3 Years

  2. Time to Maximum Observed Concentration (Tmax) of ABBV-969

    Tmax is defined as the time to maximum observed concentration of ABBV-969.

    Time frame: Up to 3 Years

  3. Terminal Phase Elimination Half-Life (t1/2) of ABBV-969

    Terminal phase elimination half-life of ABBV-969.

    Time frame: Up to 3 Years

  4. Area Under the Plasma/Serum Concentration Versus Time Curve (AUC) of ABBV-969

    Area under the plasma/serum concentration versus time curve (AUC) of ABBV-969.

    Time frame: Up to 3 Years

  5. Antidrug Antibody (ADA)

    Incidence and concentration of anti-drug antibodies.

    Time frame: Up to 3 Years

  6. Neutralizing Antibodies (nAbs)

    Incidence and concentration of neutralizing antibodies.

    Time frame: Up to 3 Years

  7. Recommended Phase 2 Dose (RP2D) of ABBV-969 (Dose-Escalation Phase)

    The RP2D of ABBV-969 will be determined during the dose-escalation phase of the study. RP2D will be determined using available safety and pharmacokinetics and pharmacodynamics data.

    Time frame: Up to 2 Years

07

Study locations

26 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 38 months is close to that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2024
First posted
Mar 19, 2024
StartActual
Mar 8, 2024
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Jun 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06318273
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 19, 2024
Start date
Mar 8, 2024
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Jun 17, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion